Opinion writers weigh in on kratom, trauma, prescription drug costs and price transparency.
Stat: Proposed Kratom Ban Would Harm The Public, Damage FDA’s CredibilityTrust in the U.S. Food and Drug Administration (FDA) declined after its approval of the controversial Alzheimer’s drug aducanumab. Three experts resigned amid allegations that the FDA had caved to industry pressure. Some argue that its credibility has reached a new low. These events should have prompted the FDA to pause, reflect, and work to repair its reputation. Instead, the agency is forging ahead with actions that may further erode its credibility. A timely example is its position on Mitragyna speciosa, commonly called kratom, a tree related to coffee plants. (Mason Marks, 8/23)
The New York Times: This Conversation Will Change How You Think About Trauma “Trauma is much more than a story about something that happened long ago,” writes Dr. Bessel van der Kolk.
Continue reading at KHN.org.